WANBURY Stock Overview
Manufactures and sells formulations and active pharmaceutical ingredients (API) in India.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Wanbury Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹155.22 |
| 52 Week High | ₹179.35 |
| 52 Week Low | ₹46.60 |
| Beta | 0.39 |
| 11 Month Change | 1.25% |
| 3 Month Change | 6.13% |
| 1 Year Change | 179.17% |
| 33 Year Change | 81.86% |
| 5 Year Change | 1,000.85% |
| Change since IPO | 12.89% |
Recent News & Updates
Statutory Earnings May Not Be The Best Way To Understand Wanbury's (NSE:WANBURY) True Position
May 24
These 4 Measures Indicate That Wanbury (NSE:WANBURY) Is Using Debt Reasonably Well
May 21Recent updates
Statutory Earnings May Not Be The Best Way To Understand Wanbury's (NSE:WANBURY) True Position
May 24These 4 Measures Indicate That Wanbury (NSE:WANBURY) Is Using Debt Reasonably Well
May 21The Market Doesn't Like What It Sees From Wanbury Limited's (NSE:WANBURY) Earnings Yet
Mar 19Wanbury Limited's (NSE:WANBURY) Shares Leap 42% Yet They're Still Not Telling The Full Story
Dec 18Estimating The Fair Value Of Wanbury Limited (NSE:WANBURY)
Sep 07Not Many Are Piling Into Wanbury Limited (NSE:WANBURY) Just Yet
Jul 16Calculating The Intrinsic Value Of Wanbury Limited (NSE:WANBURY)
Oct 27A Look At The Fair Value Of Wanbury Limited (NSE:WANBURY)
Apr 14A Look At The Fair Value Of Wanbury Limited (NSE:WANBURY)
Dec 29Are Wanbury's (NSE:WANBURY) Statutory Earnings A Good Guide To Its Underlying Profitability?
Sep 09Shareholder Returns
| WANBURY | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -5.4% | 0.9% | 1.1% |
| 1Y | 179.2% | 46.8% | 44.4% |
Return vs Industry: WANBURY exceeded the Indian Pharmaceuticals industry which returned 46.8% over the past year.
Return vs Market: WANBURY exceeded the Indian Market which returned 45.2% over the past year.
Price Volatility
| WANBURY volatility | |
|---|---|
| WANBURY Average Weekly Movement | 6.4% |
| Pharmaceuticals Industry Average Movement | 5.9% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in IN Market | 9.6% |
| 10% least volatile stocks in IN Market | 4.3% |
Stable Share Price: WANBURY has not had significant price volatility in the past 3 months.
Volatility Over Time: WANBURY's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | 1,582 | Mohan Rayana | www.wanbury.com |
Wanbury Limited manufactures and sells formulations and active pharmaceutical ingredients (API) in India. The company offers formulations for gynecology, orthopedics, heamatinics, anti-diabetic, nutraceuticals, gastro intestinal, stroke surgery, antibiotics, cough and cold solutions, anti-inflammatory, analgesics, and general practitioner. It also provides API products for anti-diabetic, anti-analgesic, anti-depressant, anti-histaminic, anti-inflammatory, anti-arthritis, anti-thrombotic, anti-epileptic, and anti-hypertensive therapeutic areas.
Wanbury Limited Fundamentals Summary
| WANBURY fundamental statistics | |
|---|---|
| Market cap | ₹5.10b |
| Earnings (TTM) | ₹559.56m |
| Revenue (TTM) | ₹5.76b |
9.1x
P/E Ratio0.9x
P/S RatioIs WANBURY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| WANBURY income statement (TTM) | |
|---|---|
| Revenue | ₹5.76b |
| Cost of Revenue | ₹3.03b |
| Gross Profit | ₹2.73b |
| Other Expenses | ₹2.17b |
| Earnings | ₹559.56m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 17.09 |
| Gross Margin | 47.43% |
| Net Profit Margin | 9.72% |
| Debt/Equity Ratio | 393.5% |
How did WANBURY perform over the long term?
See historical performance and comparison